Profilo
Tamara Byk is Vice President of Technology Platform for Evogene Ltd.
Prior to joining Evogene, she was Head of Life Science Research for Procognia Israel Ltd.
Previously, she was a Project Leader and Deputy Senior Director of Discovery and Validation for Quark Biotech (now Quark Pharmaceuticals, Inc.) from 2000 to 2004.
She received a BSc degree in Chemistry and an MSc degree in Biochemistry from the Hebrew University.
Dr. Byk holds a PhD.
Precedenti posizioni note di Tamara Byk
Società | Posizione | Fine |
---|---|---|
EVOGENE LTD. | Direttore Tecnico/Scientifico/R&S | 01/10/2009 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 01/01/2004 |
SOLEGREEN | Corporate Officer/Principal | - |
Formazione di Tamara Byk
The Hebrew University of Jerusalem | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
EVOGENE LTD. | Health Technology |
SOLEGREEN | Utilities |
Aziende private | 1 |
---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Borsa valori
- Insiders
- Tamara Byk